Tarceva and Capecitabine for Pancreatic Cancer

Inclusion Criteria: * Metastatic pancreatic carcinoma (excluding pancreatic endocrine tumors) * Only patients with measurable disease * ECOG performance status \< or equal to 1 * Life expectancy \>12 weeks * Signed informed consent * Failed or intolerance to first-line therapy for metastatic disease with a gemcitabine-containing regimen. Patients may have received adjuvant therapy in addition to one prior regimen for metastatic disease. * \>4 weeks must have elapsed from the completion of previous chemotherapy and patients must have recovered from any related toxicities * \>4 weeks must have elapsed from the participation in any investigational drug study * Laboratory values: * ANC \> 1500/mm3; * Hemoglobin \> 9.0 gm/dl; * Platelets \> 100,000/mm3; * SGOT \<2.5 X upper limit of normal; or \<5 X upper limit of normal if evidence of liver metastases; Alkaline phosphatase \< 2.5 X upper limit of normal; or \< 5 X upper limit of normal if evidence of liver metastases; Total bilirubin \< 1.5 X upper limit of normal; Creatinine clearance \> 50 cc/min (by Cockroft - Gault or as determined from a 24-hour urine collection). Exclusion Criteria: * Prior therapy with capecitabine or epidermal growth factor receptor (EGFR) inhibitors * More than one prior chemotherapy treatment regimen for metastatic disease * Clinically apparent central nervous system (CNS) metastases or carcinomatous meningitis * Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication or heart attack within the last 12 months). * Major surgery within 4 weeks of the start of study treatment, without complete recovery. * Evidence of CNS metastases (unless CNS metastases have been stable for \> 3 months) or history of uncontrolled seizures, central nervous system disorders * Uncontrolled serious medical or psychiatric illness * Women must not be pregnant or lactating * Concurrent radiation therapy * Other active malignancy * Inability to swallow tablets * Patients lacking physical integrity of the upper gastrointestinal tract or who have malabsorption syndrome * Prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil